Puma Biotechnology starts phase II lung cancer trial with alisertib

Go back to Puma Biotechnology starts phase II lung cancer trial with alisertib

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

September 17, 2026 4:07 PM EDT

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The ALISCA®-Lung2 trial is a sequential dose... More